NHS rolls out AI blood test to cut womb cancer checks
The NHS is rolling out an AI-powered blood test designed to flag womb cancer risk and spare thousands of women invasive scans. Developed by Leeds-based PinPoint Data Science, the £30 test analyses around 30 blood markers to classify patients as low, elevated, or high risk. Clinicians can use the risk score to prioritise referrals, monitor patients, or rule out cancer before hospital-based investigations.
A smarter route to diagnosis
Under the current pathway, women with symptoms such as heavy postmenopausal bleeding face a pelvic exam, transvaginal ultrasound, and sometimes a biopsy. Many find these procedures uncomfortable or distressing, yet most do not have cancer. PinPoint says its test could spare about one in five referred women from needing a transvaginal ultrasound—roughly 18,000 women a year in England. That could shorten the often protracted process, which can require multiple GP visits before cancer is ruled out.
Early data shows promise
The tool has been trialled across Yorkshire with 16,481 patients referred on urgent cancer pathways. Among women presenting with heavy bleeding, about one in 10 were found to have cancer. The test correctly flagged 99.1% of cancers as elevated or high risk and delivered a 99.8% negative predictive value for the lowest-risk group. PinPoint describes the test as a multi-cancer tool and says it is being adopted for gynaecological, lung, upper gastrointestinal, head and neck, and lower gastrointestinal pathways.
Why it matters
For patients, the test offers a less invasive route to reassurance. For the NHS, it could ease pressure on diagnostic services and shorten waiting times by focusing resources where they are most needed. If rolled out widely, the approach may set a precedent for how AI can support early cancer detection and streamline overstretched referral pathways.
Source: AI News. AI-assisted editorial synthesis — TechnoExpress.